Clinical Trial Update: Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a combination of melphalan, arsenic trioxide, and ascorbic acid in relapsed or refractory multiple myeloma has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)
• Ascorbic acid (Vitamin C)
• Melphalan (Melphalan)

Snippet

Sponsor: Oncotherapeutics | Conditions: Stage II Multiple Myeloma, Stage III Multiple Myeloma | Phase 2 | Status: WITHDRAWN